{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:39Z","timestamp":1791497919180,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015690","name":"Universitas Padjadjaran Kampus Jatinangor Sumedang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e38229","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T12:01:54Z","timestamp":1726833714000},"page":"e38229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of tofacitinib on COVID-19 patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-3117","authenticated-orcid":false,"given":"Gofarana","family":"Wilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecep","family":"Suhandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kawahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e38229_bib1","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"10.1016\/j.heliyon.2024.e38229_bib2","article-title":"Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology","volume":"39","author":"Caldwell","year":"2021","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.heliyon.2024.e38229_bib3","article-title":"Three critical clinicobiological phases of the human SARS-associated coronavirus infections","volume":"24","author":"Turk","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e38229_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.555301","article-title":"Current understanding of COVID-19 clinical course and investigational treatments","volume":"7","author":"Aguilar","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00607-2020","article-title":"Pathogenesis of COVID-19 from a cell biology perspective","volume":"55","author":"Mason","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.heliyon.2024.e38229_bib6","article-title":"Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19","volume":"35","author":"Tanner","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.heliyon.2024.e38229_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2020.08.009","article-title":"Immunopathology of hyperinflammation in COVID-19","volume":"191","author":"Gustine","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262438","article-title":"Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination","volume":"17","author":"Ramatillah","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e38229_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112419","article-title":"Interleukin-6 in SARS-CoV-2 induced disease: interactions and therapeutic applications","volume":"145","author":"Majidpoor","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e38229_bib10","article-title":"Targeting TNF-\u03b1 for COVID-19: recent advanced and controversies","volume":"10","author":"Guo","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.heliyon.2024.e38229_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib12","article-title":"Tocilizumab for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"92","author":"Boppana","year":"2022","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.heliyon.2024.e38229_bib13","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O'Halloran","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e38229_bib14","doi-asserted-by":"crossref","DOI":"10.5005\/jp-journals-10071-24029","article-title":"Cytokine storm and immunomodulation in covid-19","volume":"25","author":"Rangappa","year":"2021","journal-title":"Indian J. Crit. Care Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","volume":"86","author":"Zhang","year":"2020","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2024.e38229_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e38229_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.heliyon.2024.e38229_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-023-00345-8","article-title":"Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset","volume":"7","author":"Chebbi","year":"2023","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.heliyon.2024.e38229_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102039","article-title":"Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19","volume":"69","author":"Maslennikov","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e38229_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2016.12.004","article-title":"The methodological and reporting quality of systematic reviews from China and the USA are similar","volume":"85","author":"Tian","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2014.04.003","article-title":"Network meta-analyses could be improved by searching more sources and by involving a librarian","volume":"67","author":"Li","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2014.09.002","article-title":"The reporting characteristics and methodological quality of Cochrane reviews about health policy research","volume":"119","author":"Xiu-Xia","year":"2015","journal-title":"Health Pol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib25","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.heliyon.2024.e38229_bib26","series-title":"He Newcastle\u2013Ottawa Scale (NOQAS) for Assessing the Quality of Non-randomized Studies in Meta-Analysis, The Ottawa Hospital","article-title":"T","author":"Wells","year":"2004"},{"key":"10.1016\/j.heliyon.2024.e38229_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.heliyon.2024.e38229_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"Br. Med. J."},{"key":"10.1016\/j.heliyon.2024.e38229_bib29","article-title":"Tofacitinib associated with reduced intubation rates in the management of severe covid-19 pneumonia: a preliminary experience","volume":"25","author":"Singh","year":"2021","journal-title":"Indian J. Crit. Care Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib30","article-title":"An evaluation of efficacy and safety of tofacitinib, A JAK inhibitor in the management of hospitalized patients with mild to moderate COVID-19 - an open-label randomized controlled study","volume":"69","author":"Murugesan","year":"2022","journal-title":"J. Assoc. Phys. India"},{"key":"10.1016\/j.heliyon.2024.e38229_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13898","article-title":"Early administration of tofacitinib in COVID-19 pneumonitis: an open randomised controlled trial","volume":"53","author":"Ferrarini","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e38229_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110565","article-title":"Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19","volume":"122","author":"Almasi","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2024.e38229_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38229_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.08.031","article-title":"Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19","volume":"147","author":"Sims","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620985687","article-title":"Systematic review of immunosuppressant guidelines in the COVID-19 pandemic","volume":"12","author":"Barlow-Pay","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.heliyon.2024.e38229_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib37","doi-asserted-by":"crossref","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e38229_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-018-4299-4","article-title":"Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Huang","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e38229_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.792877","article-title":"Potential adverse events reported with the Janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews","volume":"12","author":"Song","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024142600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024142600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:51:35Z","timestamp":1789822295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024142600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2405844024142600"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38229","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tofacitinib on COVID-19 patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38229"}}